Smart, ultra-scaled, always-on wearable (and implantable) sensors are an exciting frontier of modern medicine. Among them, minimally invasive microneedles (MN) is an emerging technology platform for theragnostic applications. Compared to traditional continuous glucose measurement (CGM) devices, these MNs offer pain-less insertion and simple operation. These MN systems, however, rely on analyte diffusion from the interstitial fluid (ISF) to the sensing site, and thus, (a) introduce a substantial and intrinsic diffusion delay in sensor response, and (b) reduce the analyte concentration to which the sensor must respond. A diversity of experimental platforms has been proposed to improve performance, but their optimization relies on empirical iterative approaches. Here, we integrate the theory of transient flux balance and the biomimetic concepts from ion uptake by bacteria to derive a generalized physics-guided model for MN sensors. The framework suggests strategies to minimize response time and maximize extracted analyte concentration in terms of the geometric and physical properties of the system. Our results show that there exists an intrinsic trade-off between response time and extracted analyte concentration. Our model, validated against numerical simulations and experiment data, offers a predictive design framework that would significantly reduce the optimization time for MN-based sensor platforms.
Electrochemical immunosensors have emerged as a versatile, sensitive, and selective sensor technology of choice for a variety of applications, including detection of proteins, food pathogens, bacteria, viruses, and cancerous molecules. The combination of highly specific biorecognition elements and electrical readout systems facilitates the detection of antigens down to femtomolar concentrations. However, a lack of quantitative theoretical framework has made the design, optimization, and comparison of sensors difficult, without a clear and definitive understanding of the limits of detection, dynamic range, and sensitivity. In this paper, we integrate reaction-diffusion and effective media theories to derive a generalized scaling model for an arbitrary immunosensor that relates the relative change of redox current to the corresponding change in antigen concentration, through scaling exponents related to the geometry of biomolecules diffusion and the measurement resolution. Experimental data from dozens of immunosensors (for a variety of antigens, material systems, and sensor geometry) validate our sensor-agnostic scaling formula. Our results would allow cross-calibration of the emerging and traditional immunosensors reported across the literature and define a physics-based, standardized methodology to compare performance metrics, such as limits of detection, dynamic range, and sensitivity.
22 December 2025 in Proceedings of the National Academy of Sciences
Continuous biomarker monitoring and on-demand therapy are essential for chronic disease management, with diabetes being a key example. Although continuous glucose monitoring (CGM) and insulin pumps are moving toward a closed-loop system, it remains difficult to predict how device design influences system performance. Traditional optimization methods are inefficient and empirical: Data-driven algorithms lack interpretability, trial-and-error design is time-consuming, and first-principle models are difficult to integrate at the system level. To address these challenges, we introduce a physics-based framework which integrates microneedle (MN) designs for sensing and therapy with a physiological model of glycemic control. The framework builds compact relationships showing how material, chemical, and geometrical features affect key metrics such as response time, extraction flux, and insulin delivery rate. Specifically, we develop a theory for three sensing MN types (hollow, porous/swellable, and nanostructured MNs) and one therapeutic patch (electro-termo-mechanical device) to create a predictive model for glycemic regulation. By linking device design to system behavior across time and spatial scales, we examine the framework in three cases: How disease progression, MN design, and MN sensitivity affect plasma glucose levels and time-in-range metrics. This work establishes the foundation for a physics-based digital twin for diabetes management, complementing ML, experiments, and numerical models. More broadly, it streamlines patch design, minimizing glycemic events and trial-and-error in next-generation CGM technology.